Yearly Archives: 2015


CIRM's Klein proposes $100B biomed program

Bob Klein describes his vision of how to increase biomedical funding to hasten discovery and commercialization of disease treatments. He spoke Thursday, Feb. 19, at the annual UCSD Moores Cancer Center symposium.

The main architect of California's groundbreaking 2004 stem cell initiative has proposed a $100 billion international bond program in life sciences, to speed up research and clinical testing of disease therapies. The program would be focused on stem cells and genomics.

Bob Klein, a real estate developer who spearheaded the creation of the California Institute for Regenerative Medicine, unveiled his proposal at at last Thursday's UCSD Moores Cancer Center symposium.

The United States and a few other countries would jump-start the program and other countries would join, said Klein, a real estate investor. He likened the international participation to that already taking place with CIRM, created by the 2004 initiative, Proposition 71. CIRM got $3 billion from that initiative; the total to be repaid by taxpayers is $6 billion, including interest.

The stem cell agency has partnered with 14 other countries to co-fund international research projects. Foreign partners fund scientists in their own countries, while CIRM funds California-based scientists. Klein was CIRM's first chairman. Although he left the agency's governing board in 2011, he remains involved in advancing the agency's objectives.

This partnership leverages funding to create a much greater total impact, Klein said in an on-stage interview with Rep Scott Peters, D-San Diego. Peters, one of the post prominent supporters of federal biomedical funding in Congress, represents much of San Diego's biotech heartland of La Jolla and Sorrento Valley. Beside the financing issues, they also discussed ways to increase political support for biomedical research.

Klein drew from his real estate knowledge of crafting bonds to describing how the program would work. The bond program would be seeded by a much smaller amount of seed funding through government-supported agencies, creating leverage.

"Just to give you (an idea) of the multiple effect of bringing critical funds upfront in the process, $100 million (a year) in bonds at the World Bank borrowing rate creates about $2.5 billion in bonds that are supported," Klein said. "At a time of scarce resources for Congress, if they would appropriate on a long term commitment to support international bonds, we could really leverage up to maybe a $100 billion program."

Under that program, each participating country would be allocated an amount of upfront financing to pay.

"Because the borrowing is so much cheaper than anything a country can do, from the surplus funds we raise, which are about 35 percent to 40 percent more than most countries can raise from the same amount of money, we can have an international pool, where we can collaborate and compete through peer review," Klein said.

Follow this link:
CIRM's Klein proposes $100B biomed program

ESI BIO A Division of BioTime, Inc., Announces Alliance Agreement with Pivotal Scientific Ltd for Distribution of …

ALAMEDA, Calif.--(BUSINESS WIRE)--ESI BIO, the stem cell products division of BioTime, Inc., providing stem cells and stem cell research reagents world-wide, and Pivotal Scientific Ltd, a company specializing in developing the international growth of biotech enterprises, announced an alliance agreement to develop business opportunities and manage ESI BIOs growing network of new international distributors.

ESI BIOs (esibio.com) research products are used by stem cell researchers around the world and include clinical and research grade human embryonic stem cells from ES Cell International (ESI) and HyStem hyaluronan-based hydrogel extracellular matrices. ESI BIO also provides unique PureStem embryonic progenitors, antibodies, and small molecules for stem cell differentiation and reprogramming.

Under the new agreement, Pivotal Scientific will use its experience and contacts in the biologic research field to develop opportunities for ESI BIO and will handle a network of new distributors for ESI BIO products. ESI BIO has a lot to offer researchers, said James Mosedale, Business Development Director, at Pivotal, not just in terms of excellent products, but their focus on clinically-relevant products is a novel selling point, especially as researchers are looking to treat and cure disease. Were looking forward to doing our best to get these products into the hands of more researchers worldwide.

Were very pleased to have signed this agreement to have Pivotal Scientific working on our behalf, said Jeffrey Janus, CEO of ESI BIO. Pivotal Scientific can help us develop our world-wide distribution network, and has the right combination of experience and contacts to make our distribution strategies succeed.

About ESI BIO

ESI BIO - A division of BioTime, Inc., is a unique research reagent organization which markets and distributes stem cell related research products provided by BioTime and its subsidiary companies. Many of these products can be provided as a research grade or clinical grade, including ES Cell Internationals human embryonic stem cell lines and HyStem hyaluronan-based hydrogels produced under conditions designed to be compliant with principles of current Good Manufacturing Practices (cGMP), making them suitable for use in clinical research and regenerative medicine. ESI BIO's portfolio includes PureStem human embryonic progenitors, antibodies, and small molecules for stem cell differentiation and reprogramming. ESI BIO's mission is to develop innovative research products that help translate scientific discoveries to the clinic. ESI BIO facilities are located in La Jolla and Alameda, California. Learn more at http://www.esibio.com.

About Pivotal Scientific Ltd

Pivotal Scientific Ltd (PSL) is a consultancy working specifically with manufacturers developing reagents for life science research. PSL works with start-ups to help develop their business, sales and marketing strategies, with small and medium enterprises looking to take the next step and grow internationally and larger companies looking to acquire other companies. Learn more at http://www.pivotalscientific.com.

Read more from the original source:
ESI BIO A Division of BioTime, Inc., Announces Alliance Agreement with Pivotal Scientific Ltd for Distribution of ...

Europe Approves Holoclar, the First Stem Cell-Based Medicinal Product

PARMA and MODENA, Italy, February 23, 2015 /PRNewswire/ --

The collaborationbetween a public excellent researchcenteranda solidprivate pharmaceuticalcompany allowed toachievean extraordinary result, entirely "made in Italy":the first medicinal productcontainingstem cellsapproved in the Western world

The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea damage. Holoclar is manufactured by Holostem Terapie Avanzate (HolostemAdvanced Therapies) - a spin-off of the University of Modena and Reggio Emilia - at the Centre for Regenerative Medicine "Stefano Ferrari" (CMR) of the same University.

(Logo: http://photos.prnewswire.com/prnh/20150223/731609-a )

(Logo: http://photos.prnewswire.com/prnh/20150223/731609-b )

(Logo: http://photos.prnewswire.com/prnh/20150223/731609-c )

"Holoclaris theveryfirstmedicinalproductbased onstem cellsto beapproved andformallyregisteredin the Western world," states AndreaChiesi, Director of R&D Portfolio Management of Chiesi Farmaceutici S.p.A. and CEO of Holostem Terapie Avanzate. "This record," continues AndreaChiesi,"shows that thepartnershipbetween the public and privatesectorsis not only possible,butisprobably the best strategy for the development of stem cell-based regenerative medicine, particularly when autologous cells are used.Holostemisnowconsideredasabusiness modeltotranslate into clinicstheresultsobtained byscientific researchin this field." Underlying Holoclar are more than 20 years of excellence in research, conducted by a team of internationally renowned scientists in the field of epithelial stem cell biology aimed at clinical translation. European Directive 1394/2007 substantially equalizes advanced cell therapies to medicines and imposes, among other things, that cell cultures has to be manufactured only in GMP-certified facilities (GMP: Good Manufacturing Practice). Thanks to the investments of Chiesi Farmaceutici, the Centre for Regenerative Medicine in Modena - where Holostem operates - was certified as GMP compliant and continue to follow the path towards the registration of this newly developed advanced therapy.

"The authorization processhas been long andcomplex, butthe resultachievedtodayshows thatcellscan beculturedaccording topharmaceutical standardsappropriateto guaranteesafety and efficacy," adds Professor MicheleDeLuca, Scientific Director and co-founder of Holostem, as well as Director of the CMR of the University of Modena. "In addition,ina periodof great confusionabout the realtherapeutic possibilitiesof stem cells,such as the onewe are living in, being ableto demonstratethatstem cells can be definitely safe and successful in a controlled clinical settingismore important than ever." To explain how Holoclar works is Professor GraziellaPellegrini, Coordinator of cell therapy at CMR, as well as director of R&D and co-founder of Holostem, who authored, together with Professor De Luca, the research and designed the product development: "Afterdevelopingcell culturesbased onepithelial stem cellsfor the treatmentofvariousdisorders ofthestratifiedepithelia-from the skinfor full-thicknessburnsto the reconstructionof the urethra-wediscoveredthatthe stem cellsthat allowthe regenerationof the cornearesidein asmall areaatthe borderbetween the cornea(the transparent partat thecenter of the eye)andthe conjunctiva(the contiguous white part),which is called'the limbus'.Whenthermal or chemicalburnsof theocular surfacedamageirreversiblythisstemcellreserve,thecorneal surface-whichin ahealthy eyecompletely renews itself approximatelyeverysix/ninemonths-stopsregeneratingand the conjunctivagraduallybegins tocover thecorneawithawhite coating,thatprevents visionand causes chronicpainandinflammation.Ifinat leastone of the eyes of the patientevenasmallresidueofundamaged limbus is left,we areable to reconstructin a laboratorythe epitheliumthat covers thecorneal surface,thanks to thestem cells harvestedthrough a 1-2mmbiopsy.Thisgraftofepithelium-Holoclar, precisely-that looks likea kind ofcontactlens,is thentransplantedinto the patientandallows to obtain along-termtransparent corneaanda full recoveryof visual acuity,without causing anyrejection reaction,because itconsists of cellsof the patient him/herself."

This therapy, experimentally applied for the first time in humans in the nineties, and designated as orphan drug in 2008, thanks to the registration obtained today, in the near future will be available to all European patients who have suffered workplace injuries (caused, for example, by burnt lime, solvents or acids), domestic accidents (for example eye burns caused in adults and children by detergents or abrasive agents) or - as unfortunately reported by the press in the past few months - in the cases of assault with chemical agents.

Meanwhile, the research in Modena does not stop. The next goal of the team of Emilian researchers and entrepreneurs is to develop new advanced therapy products, such as the gene therapy for the treatment of epidermolysis bullosa, or "Butterfly disease", to date used successfully in the first two patients ever. And to develop new experimental and clinical protocols using different stem cells of stratified epithelia, such as conjunctiva, urethra, oral mucosa and respiratory epithelia.

Here is the original post:
Europe Approves Holoclar, the First Stem Cell-Based Medicinal Product

Stem Cell Research & Therapy | Full text | Aromatic …

Abstract Introduction

Aromatic (ar-) turmerone is a major bioactive compound of the herb Curcuma longa. It has been suggested that ar-turmerone inhibits microglia activation, a property that may be useful in treating neurodegenerative disease. Furthermore, the effects of ar-turmerone on neural stem cells (NSCs) remain to be investigated.

We exposed primary fetal rat NSCs to various concentrations of ar-turmerone. Thereafter, cell proliferation and differentiation potential were assessed. In vivo, nave rats were treated with a single intracerebroventricular (i.c.v.) injection of ar-turmerone. Proliferative activity of endogenous NSCs was assessed in vivo, by using noninvasive positron emission tomography (PET) imaging and the tracer [18F]-fluoro-L-thymidine ([18F]FLT), as well as ex vivo.

In vitro, ar-turmerone increased dose-dependently the number of cultured NSCs, because of an increase in NSC proliferation (P<0.01). Proliferation data were supported by qPCR-data for Ki-67 mRNA. In vitro as well as in vivo, ar-turmerone promoted neuronal differentiation of NSCs. In vivo, after i.c.v. injection of ar-turmerone, proliferating NSCs were mobilized from the subventricular zone (SVZ) and the hippocampus of adult rats, as demonstrated by both [18F]FLT-PET and histology (P<0.05).

Both in vitro and in vivo data suggest that ar-turmerone induces NSC proliferation. Ar-turmerone thus constitutes a promising candidate to support regeneration in neurologic disease.

Curcumin and ar-turmerone are the major bioactive compounds of the herb Curcuma longa. Although many studies have demonstrated curcumin to possess antiinflammatory and neuroprotective properties (reviewed by [1]), to date, the effects of ar-turmerone remain to be elucidated. For example, antitumor properties, exerted via the induction of apoptosis [2] and inhibition of tumor cell invasion [3], have been attributed to ar-turmerone. Park et al. [4,5] recently suggested that ar-turmerone also possesses antiinflammatory properties resulting from the blockade of key signaling pathways in microglia. Because microglia activation is a hallmark of neuroinflammation and is associated with various neurologic disorders, including neurodegenerative diseases [6,7] and stroke [8,9], ar-turmerone constitutes a promising therapeutic agent for various neurologic disorders.

The regenerative potential of endogenous neural stem cells (NSCs) plays an important role in neurodegenerative disease and stroke. Endogenous NSCs are mobilized by cerebral ischemia [10] as well as by various neurodegenerative diseases [11,12], although their intrinsic regenerative response is insufficient to enable functional recovery. The targeted (that is, pharmacologic) activation of endogenous NSCs has been shown to enhance self-repair and recovery of function in the adult brain in both stroke [13,14] and neurodegeneration [15]. Importantly, NSCs and microglia relevantly interact with each other, thereby affecting their respective functions [16,17].

Thus, with the perspective of ar-turmerone as a therapeutic option in mind, we investigated the effects of ar-turmerone on NSCs in vitro and in vivo.

NSCs were cultured from fetal rat cortex at embryonic day 14.5, as described previously [18]. Cells were expanded as monolayer cultures in serum-free DMEM/F12 medium (Life Technologies, Darmstadt, Germany) with N2 supplement (Gibco, Karlsruhe, Germany) and fibroblast growth factor (FGF2; 10ng/ml; Invitrogen, Karlsruhe, Germany) for 5days and were replated in a 24-well plate at 10,000 cells per cm2. FGF2 was included throughout the experiments.

Ar-turmerone (Fluka, Munich, Germany) was added to cultures at replating at concentrations of 0, 1.56, 3.125, 6.25, 12.5, and 25g/ml. All experiments were performed in triplicate. After 72hours, representative pictures were taken by using an inverted fluorescence phase-contrast microscope (Keyence BZ-9000E). Three images were taken per well, and cells were counted by using the software ImageJ with a threshold of 20 px (National Institutes of Health, Bethesda, MD, USA, Version 1.47k).

See the rest here:
Stem Cell Research & Therapy | Full text | Aromatic ...

Brave gran set to take on 10,000ft skydive to help pay for life-saving medical treatment for daughter

A GRAN who is afraid of heights is set to skydive from 10,000ft to help pay for life-saving medical treatment for her daughter.

Margaret Clarke, 70, aims to overcome her lifelong fear so Lucy, 38, can travel to Moscow for a pioneering stem cell transplant to stop the progression of Multiple Sclerosis.

The skydive over St Andrews, Fife is one of several fundraising initiatives Lucy's family are undertaking to raise the 40,000 needed for the treatment.

If the mum-of-one can secure funding she will be the first Scot to fly to Russia for the cutting edge procedure.

Margaret, of Rosehall, Sutherland, said: Which mother wouldnt jump out of a plane at 10,000 feet if they thought it would save their daughter?

I dont think Im any different from any other caring mother.

Lucy has suffered terribly with her illness.

Multiple Sclerosis is a disease that gets progressively worse over time.

If we dont act now, I dont want to think about where we will be in a few years time.

The jump on March 29 is one of a number of charity events planned to raise money for mum-of-one Lucy's treatment.

Originally posted here:
Brave gran set to take on 10,000ft skydive to help pay for life-saving medical treatment for daughter

You could be the match and save someone's life

To what length would you go to save someone's life, a stranger's life at that?

It's a question Be The Match group representatives are asking you as every ten minutes someone who has blood cancer dies.

We're talking about people diagnosed with leukemia, lymphoma and sickle cell anemia.

For hundreds of patients each year, their only hope for survival is a bone marrow or stem cell transplant.

"My doctors told me, you can go through a transplant or you can die," said John Philpott, Be The Match community engagement representative. "Those were my only choices."

Fortunately, for John Philpott who was diagnosed with leukemia in 2012, he eventually heard the words "We found a match."

Philpott, like many others, 70 percent, to be exact, do not find a matched donor within their family.

After beating cancer, he nabbed a job working for the group that saved his life.

"The number one thing that Be The Match does is provide hope patients who have no other choice than to receive a transplant," Philpott said.

Friday, Feb. 20 and Saturday, Feb. 21, people can sign up to be a part of the registry. You have to be between the ages of 18-44 years old.

View original post here:
You could be the match and save someone's life

Stem Cell Therapy Using Fat Cells – Howard Beach, Ozone Park, Queens NY – Dr. Benjamin Bieber, MD – Video


Stem Cell Therapy Using Fat Cells - Howard Beach, Ozone Park, Queens NY - Dr. Benjamin Bieber, MD
Regenerative Medicine - Dr. Benjamin Bieber, MD - Howard Beach, Ozone Park, Queens NY http://www.crossbaypmr.com Phone: (718) 835-0100 Stem Cell Therapy Using Fat Cells Dr. Benjamin...

By: wpv wpvmedia

Continue reading here:
Stem Cell Therapy Using Fat Cells - Howard Beach, Ozone Park, Queens NY - Dr. Benjamin Bieber, MD - Video

What is Bone Marrow Aspirate Concentrate (BMAC) in Stem Cell Therapy? – Video


What is Bone Marrow Aspirate Concentrate (BMAC) in Stem Cell Therapy?
Dr. McKenna explains bone marrow aspirate concentrate (BMAC). BMAC contains stem cells and growth factors that can build blood supply and heal tissue. For more information: http://www.rmiclinic.com...

By: Riordan-McKenna Institute

Go here to see the original:
What is Bone Marrow Aspirate Concentrate (BMAC) in Stem Cell Therapy? - Video

Ryan Benton Discusses Stem Cell Therapy for Duchenne’s Muscular Dystrophy – Video


Ryan Benton Discusses Stem Cell Therapy for Duchenne #39;s Muscular Dystrophy
Ryan Benton is the first patient in the United States to receive human umbilical cord-derived mesenchymal stem cell therapy for Duchenne #39;s muscular dystrophy. The US FDA granted Ryan this...

By: http://www.cellmedicine.com

Visit link:
Ryan Benton Discusses Stem Cell Therapy for Duchenne's Muscular Dystrophy - Video

Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage – 6 Months After Stemcell Transplant – Video


Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage - 6 Months After Stemcell Transplant
Bruce from Perth Australia give us an update 6 Months After his cord Mesenchymal stem cell treatment for Iiver cirrhosis, kidney complications in Thailand: More here: http://stemcellthailand.org/th...

By: Regeneration Center of Thailand

See original here:
Stem Cell Therapy for Liver Failure Cirrhosis Kidney Damage - 6 Months After Stemcell Transplant - Video